Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK PM reassures over AstraZeneca jab as under-30s offered alternative

Thu, 08th Apr 2021 06:34

(Alliance News) - Prime Minister Boris Johnson has sought to reassure the public the Oxford/AstraZeneca PLC vaccine is safe after UK regulators said there was a possible link between the jab and "extremely rare" blood clots.

The Medicines & Healthcare products Regulatory Agency said the benefits still outweigh the risks overall but while it has not concluded that the vaccine causes rare brain clots, it said the link is getting firmer.

Regulators have recommended that people aged 18 to 29 should be offered the Pfizer, Moderna or other vaccines that come on stream as the programme continues to rollout across the UK.

It comes as the family of a solicitor who died from a blood clot after receiving an AstraZeneca vaccine urged the public to "keep saving lives" by taking up a jab when offered it.

The prime minister sought to boost public confidence in the Oxford-developed shot as he said the changes in its use would not force a change in the road map out of lockdown.

Johnson told reporters in Cornwall: "These vaccines are safe, they've saved many thousands of lives and people should come forward to get their jabs and we'll make sure that they get the right jabs."

MHRA's chief executive Dr June Raine told a press conference that there was a "reasonably plausible" link between the AstraZeneca jab and rare blood clots, but stressed these were "extremely rare".

She said: "Based on the current evidence, the benefits of the Covid-19 vaccine AstraZeneca against Covid-19 and its associated risks – hospitalisation and death – continues to outweigh the risks for the vast majority of people.

"Our review has reinforced that the risk of this rare suspected side effect remains extremely small."

Meanwhile the family of Neil Astles, 59, who died in hospital on Easter Sunday after receiving his first AstraZeneca jab dose on March 17, told the Telegraph that they wanted the public to continue taking up the vaccine.

Dr Alison Astles told the newspaper: "If we all have the vaccine, a few of us might have a blood clot but the evidence is that fewer people will die.

"We trust the process, we trust the regulator, and despite what has happened to our family, we don't want people to be scared off. That's the message we want to get across."

A separate review by the European Medicines Agency (EMA) concluded on Wednesday that "unusual blood clots with low blood platelets should be listed as very rare side effects" of the AstraZeneca vaccine.

The MHRA said that up to March 31, across the UK it had received 79 reports of blood clots accompanied by low blood platelet count, all in people who had their first dose of the vaccine, out of around 20 million doses given.

Of these 79, a total of 19 people have died, the regulator said, although it has not been established what the cause was in every case. Of the 19 who died, three were under the age of 30.

The figures suggest the risk of rare blood clot is the equivalent to four people out of every million who receive the vaccine.

The MHRA said that those who have had their first dose of the AstraZeneca vaccine should still get their second dose.

Only those who suffered a rare blood clot after the first dose should not get vaccinated.

Anyone with blood disorders that leave them at risk of clotting should discuss the benefits and risks of vaccination with their doctor before going for a jab.

In Europe, the EMA has carried out an in-depth review of 62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis, in which 18 people died.

Health Secretary Matt Hancock said on Twitter that the findings by the MHRA and EMA had confirmed that the AstraZeneca jab was "safe" and that the benefits of the jab "far outweigh the risks for the vast majority of adults".

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2023 17:44

UK's FTSE 100 ends flat as BOJ sparks rate worries, higher on the week

AstraZeneca boosts pharma index to one-month high

*

Read more
28 Jul 2023 17:31

European shares slip overall but German blue-chips hit record high

STOXX 600 dips 0.2% but posts weekly gains

*

Read more
28 Jul 2023 12:10

AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up

Q2 sales and earnings beat estimates

*

Read more
28 Jul 2023 09:13

AstraZeneca's rare disease arm in $1 bln deal for Pfizer gene therapies

July 28 (Reuters) - AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the British drugmaker bets on new genetic therapies.

Read more
28 Jul 2023 08:52

LONDON MARKET OPEN: StanChart, AstraZeneca lift FTSE 100 into green

(Alliance News) - Stock prices in London opened higher on Friday, boosted by a mostly strong set of company earnings, while investors weighed recent central bank decisions.

Read more
28 Jul 2023 08:51

TOP NEWS: AstraZeneca profit surges as Alexion agrees Pfizer deal

(Alliance News) - AstraZeneca PLC on Friday reported half-year profit more than quintupling amid much lower costs, as its rare disease focused unit Alexion signed an agreement with Pfizer.

Read more
28 Jul 2023 07:54

LONDON BRIEFING: NatWest posts interim growth; IAG swings to profit

(Alliance News) - Stocks in London are called slightly lower on Friday, with investors having plenty to consider amid the week's swathe of corporate earnings and central bank decisions.

Read more
28 Jul 2023 07:04

AstraZeneca posts strong first half despite Covid drug weakness

(Sharecast News) - Pharmaceuticals giant AstraZeneca reported strong first-half growth on Friday, despite challenges related to the decline of Covid-19 medicines.

Read more
27 Jul 2023 21:08

IN BRIEF: Astra drug approved while another shows promise

AstraZeneca PLC - Cambridge-based pharmaceutical firm - Says Soliris approved in EU for treatment of refractory generalised myasthenia gravis in those aged between six and 17. "This is the first and only targeted therapy approved for the treatment of paediatric patients with the disease in the EU," AstraZeneca says. Myasthenia gravis is a disease that causes muscle weakness. Separately, Astra says Enhertu shows meaningful progression-free survival and overall survival in some cancer sufferers. The measures are two secondary endpoints of a phase II trial. Enhertu is being jointly-developed by Astra and Daiichi Sankyo Co Ltd.

Read more
27 Jul 2023 18:07

Bristol Myers sales fall, cuts 2023 forecast as drugs face competition

Q2 revenue at $11.23 bln, misses analysts' estimate

*

Read more
25 Jul 2023 12:07

IN BRIEF: OTAQ names interim finance chief with incumbent to move on

OTAQ PLC - Lancaster, England-based marine technology company, focused on offshore oil and gas industries and aquaculture - Chief Financial Officer Matt Enright resigns effective July 31, to assume a new role outside OTAQ. He was hired as CFO in April 2020. OTAQ appoints Justine Dowds, previously managing director at GB3 Ltd until May, as interim CFO. Dowds was also finance director at Pool Aviation Ltd from 2007 to 2015, and prior to that was financial controller at United Utilities Group PLC and an accountant at AstraZeneca PLC. Enright says: "I believe the company is now well placed to benefit from the investments in resource and products made over the past three years, placing OTAQ on a sound growth path."

Read more
20 Jul 2023 14:35

Activist investor Elliott takes stake in drug manufacturer Catalent - source

LONDON, July 20 (Reuters) - Activist investor Elliott Investment has taken a stake in contract drugmaker Catalent , a source familiar with the matter told Reuters on Thursday.

Read more
18 Jul 2023 08:10

AstraZeneca, Sanofi infant respiratory treatment gets US approval

(Sharecast News) - AstraZeneca and Sanofi's Beyfortus drug has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants, the two companies said on Tuesday.

Read more
18 Jul 2023 07:48

LONDON BRIEFING: Ocado backs annual guidance as interim loss widens

(Alliance News) - Stocks in London are set to tread water on Tuesday, as investors look ahead to US corporate earnings and economic data.

Read more
18 Jul 2023 06:04

Rishi Sunak to meet bosses at inaugural Business Council gathering

(Alliance News) - Bosses from AstraZeneca PLC, Alphabet Inc's Google, Shell PLC and other major companies will gather in Downing Street on Tuesday for the first meeting of Rishi Sunak's Business Council.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.